Skip to main content
Regencell Bioscience Holdings Ltd logo

Regencell Bioscience Holdings Ltd - Investor Relations & Filings

Listed IPO Jul 2021
Ticker · RGC ISIN · KYG7487R1002 US Manufacturing
Open in API
Filings indexed 80 across all filing types
Latest filing 2021-12-30 Major Shareholding Noti…
Country US United States of America
Listing US RGC · 3 venues

Key figures FY2024

Period ended 2024-06-30 · USD
Headline annual figures for Regencell Bioscience Holdings Ltd, fiscal year 2024, reported in USD, with the source filing for each figure.
Total Revenues USD 0 per the Annual Report filed 2024-10-25
Net Income USD -4.36M per the Annual Report filed 2024-10-25
Total Assets USD 8.44M per the Annual Report filed 2024-10-25
Total Equity USD 8.22M per the Annual Report filed 2024-10-25
Cash from Ops USD -4.00M per the Annual Report filed 2024-10-25

As reported by the issuer in the filings linked above. Figures are normalized for comparability; consult the source filing for the authoritative statement.

About Regencell Bioscience Holdings Ltd

https://www.regencellbioscience.com/

Regencell Bioscience Holdings Ltd. is an early-stage bioscience company that focuses on the research, development, and commercialization of proprietary Traditional Chinese Medicine (TCM) formulations. The company's primary therapeutic focus is on treating neurocognitive and neurodevelopmental disorders, specifically Attention Deficit Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD). It aims to develop natural and effective treatments to improve the quality of life for patients and their families, with the goal of becoming a global market leader in this field.

Recent filings

Filing Released Lang Actions
AMENDMENT NO. 2 TO SCHEDULE 13D
Major Shareholding Notification
2021-12-30 English
SCHEDULE 13G
Major Shareholding Notification
2021-12-15 English
REPORT OF FOREIGN PRIVATE ISSUER
Board/Management Information Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Regencell Bioscience Holdings Limited, with the SEC. It announces the appointment of a new independent director, Dr. Wing Yan (William) Lo, including details about his role, compensation, and biographical information. The document does not contain financial statements or detailed financial performance data. It is focused on management/board changes. Therefore, it fits the category of Board/Management Information (MANG). The document length is 5274 characters, which is sufficient to provide substantive information about the appointment rather than a brief announcement. Hence, the classification is MANG with high confidence.
2021-12-13 English
AMENDMENT NO. 1 TO SCHEDULE 13D
Major Shareholding Notification
2021-11-22 English
Board/Management Information 2021
Board/Management Information Classification · 100% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, Regencell Bioscience Holdings Limited. The content reports the resignation of an independent director from the board, including details about the director's roles and the effective date of resignation. There are no financial statements, earnings data, or detailed management discussion. The document is short (2236 characters) and focuses solely on a board/management change. Therefore, it fits the category of Board/Management Information (MANG).
2021-11-17 English
ANNUAL REPORT
Annual Report FY 2021
2021-10-29 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.